The Claim
In patients who have not previously taken statins and who have experienced a myocardial infarction, delaying the initiation of ezetimibe beyond 12 weeks is associated with a higher risk of major adverse cardiovascular events over a 3-year period compared to initiating ezetimibe within 12 weeks, with a hazard ratio of 1.14 (95% CI: 0.95–1.41), although this difference is not statistically significant.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If someone has a heart attack and hasn’t taken cholesterol drugs before, waiting more than 12 weeks to start a drug called ezetimibe might increase their risk of future heart problems — though the data isn’t strong enough to be sure.
See the scientific wording
In statin-naïve patients following myocardial infarction, delaying ezetimibe initiation beyond 12 weeks is associated with a higher risk of major adverse cardiovascular events compared to initiation within 12 weeks, with a 3-year hazard ratio of 1.14 (95% CI: 0.95–1.41), though the difference did not reach statistical significance.
What the research says
1 studyThe study found that starting ezetimibe more than 12 weeks after a heart attack was linked to a slightly higher risk of heart problems over 3 years, but the difference wasn’t strong enough to rule out chance. This matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.